Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOOST: INTENSIFY BASAL
NCT01045447Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2010
- Primary completion
- Oct 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of insulin degludec + insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in Glycosylated Haemoglobin at 26 weeks. Started Jan 2010; status: completed.
02
Drugs
insulin degludec + insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01045447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01045447.